Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTAIN: FF/UMEC/VI vs FF/VI in Inadequately Controlled Asthma
NCT02924688Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2016
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of fluticasone furoate + umeclidinium bromide + vilanterol trifenatate in asthma (6 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second at 24 weeks. Started Oct 2016; status: completed.
02
Drugs
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02924688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924688.